Merci360

Merci360 is a Japanese biotechnology company specializing in the development of regenerative medicines using induced pluripotent stem cell (iPSC) technology. The company focuses on the mass production of iPSC-derived mesenchymal stem cells (iMSCs), which offer improved consistency and scalability compared to traditional donor-derived MSCs. Their therapeutic pipeline targets inflammatory and fibrotic diseases, including Graft-versus-Host Disease (GvHD) and liver cirrhosis. By leveraging a proprietary manufacturing platform, Merci360 aims to provide standardized, high-quality cell therapies for global clinical applications. The company was established as a spin-off from research conducted at Keio University School of Medicine.